González GG, Salmon GSL

Language: Spanish
References: 14
Page: 881-887
PDF size: 134.20 Kb.

ABSTRACT

A study of therapeutic intervention was carried out, in order to determine the clinical improvement and laboratory results in 163 children affected by sickle cell anemia and who were treated with hydroxyurea, and who were assisted in the Southern Children Hospital in Santiago de Cuba from September, 2009 to the same month of 2010. For this, an intentional sample of 22 patients was selected, taking into account the inclusion and exclusion criteria, number of clinical events, laboratory parameters, transfusions and admissions in a year with the use of the medication. After some months of initiating the treatment, they were compared with the same indicators. When concluding the investigation it was verified that hydroxyurea had increased the fetal hemoglobin levels and decreased the occurrence of clinical events, among which there were: vasoocclusive and central nervous system crisis, acute thoracic syndrome and infections.

REFERENCES

1. Machín García S, Svarch Guerchicoff E, Agramonte Llanes OM, Núñez Quintana A, Menéndez Veitía AF, Hernández Padrón C, et al. Tratamiento con dosis moderada de hidroxiurea en la drepanocitosis. Rev Cubana Hematol Inmunol Hemoter. 2008 [citado 17 oct 2009];24(2). Disponible en: http://www.imbiomed.com.mx/1/1/articulos.php?method=showDetailarticulo53497idseccion661idejemplar5413revista66

2. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cells disease. Life expectancy and risk factors for early death. N Eng J Med.1994;330(23):1639-44.

3. Halsey C, Roberts IAG. The role of hydroxyurea in sickle cell disease. Br J Haematol.2003;120(2):177-86.

4. Powars D, Chan LS, Schroeder Wa. The variable expression of sickle cell disease is genetically determined. Semin Hematol.1990;27(4):360-76.

5. Stuart M, Nagel R. Sickle-cell disease. Lancet. 2004;364:1343-59.

6. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95(6):1918-24.

7. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Eng J Med.1995;332:1317-22.

8. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, et al. Safety of hydroxyurea in children with sickle cell anemia:results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood.1999;94(5):1550-4.

9. Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood.2001;97(11):3628-32.

10. Zora RR, Buchanan GR. Expanding the role of hydroxyurea in children with sickle cell disease. J Pediatr.2004;145(3):287-8.

11. Steinberg MH, Lu ZH, Borton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood.1997;89(3):1078-88.

12. Ware RE, Eggleston B, Redding Lallinger R, Wang WC, Smith Whitley K, Daeschner C, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood.2002;99(1):10-4.

13. Orringer EP, Blythe DS, Johnson AE, Phillips G Jr, Dover GJ, Parker JC. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood.1991;78(1):212-6.

14. Ballas SK, Dover GJ, Charache S. Effets of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol.1989;32(2):104-11.